SOAT1 and myelofibrosis: Heine et al., 2013 found that the Janus kinase (JAK)–inhibitor, ruxolitinib, reduced DC activation, and treated myelofibrosis by deregulating JAK-STAT (signal transducer and activator of transcription) signaling. JAK-STAT signaling pathway can selectively influence the maturation, activation, and function of DCs by the JAK protein family, downstream STAT proteins, and types I and II cytokine receptors associated with JAK (Schindler et al., 2007; Kim et al., 2015).